GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: AZD-2389 | example 67 [WO2022130270A1]
Compound class:
Synthetic organic
Comment: The chemical structure of AZD2389 was disclosed during the 'First Time disclosures' session at the ACS Spring 2025 meeting in San Diego [2]. This matches one of the compounds claimed in Astrazeneca's patent WO2022130270A1 [1]. AZD2389 is proposed to inhibit the prolyl endopeptidase activity of fibroblast activation protein (FAP; i.e. inhibition of cleavage of FGF21 and α2-antiplasmin/α2-AP), as a mechanism to treat liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) where elevated FAP expression drives pathogenic hepatic fibroblasts.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
AZD2389 inhibits activity of plasma FAP in human, mouse and monkey plasma with sub-nanomolar potencies [1]. IC50 for inhibition of prolyl endopeptidase (PREP) is 1200 nM. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|